title: Use of insulin to improve [18 F]fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking.
abstract: While 18F-FDG labelling of monocytes would allow in vivo trafficking with positron emission tomography (PET), present methods suffer from poor retention of radioactivity. We investigated the feasibility of utilizing insulin for improved [18F]fluorodeoxyglucose (18F-FDG) labelling. Separated human monocytes and lymphocytes were labelled with 18F-FDG with or without 3 h insulin pre-incubation. Insulin had no effect on lymphocyte labelling (21.4+/-0.8% vs 20.8+/-1.1% efficiency, P=NS). However, for monocytes, insulin pre-incubation led to a 169+/-9% increase in labelling efficiency (19.3+/-4.1 vs 32.5+/-1.8, P<0.05), without significant effects on cell activation or viability. Moreover, while only 57.7+/-4.8% and 40.4+/-5.6% of the 18F-FDG was retained at 1 and 3 h for controls, the retention rate increased to 91.6+/-2.1% (P=0.01) and 86.5+/-1.9% (P<0.01) after insulin pre-incubation. Improved 18F-FDG retention was accompanied by a 70.3+/-7.4% decrease in glucose-6-phosphatase activity (P=0.02). PET imaging of rats showing hepatic ischaemia-reperfusion injury demonstrated higher liver uptake for monocytes labelled after insulin treatment. Thus, insulin improves monocytic 18F-FDG uptake and retention, and may provide a feasible labelling method for PET imaging.
authors.affiliation: Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: J-Y
authors.initials: JY
authors.lastname: Paik
authors.forename: K-H
authors.initials: KH
authors.lastname: Lee
authors.forename: S-S
authors.initials: SS
authors.lastname: Byun
authors.forename: Y S
authors.initials: YS
authors.lastname: Choe
authors.forename: B-T
authors.initials: BT
authors.lastname: Kim
mesh_terms: D000818:Animals; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005952:Glucose-6-Phosphatase / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology*; D008099:Liver / Q000098:blood supply / Q000000981:diagnostic imaging / Q000378:metabolism; D008214:Lymphocytes / Q000000981:diagnostic imaging / Q000378:metabolism; D008297:Male; D023421:Models, Animal; D009000:Monocytes / Q000000981:diagnostic imaging* / Q000378:metabolism*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000000981:diagnostic imaging / Q000378:metabolism; D012680:Sensitivity and Specificity; D013997:Time Factors; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005952:Glucose-6-Phosphatase